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Prevalence and factors associated with
asthma among adolescents and adults in
Uganda: a general population based survey
Bruce J. Kirenga1* , Corina de Jong2,3, Winceslaus Katagira4, Samuel Kasozi4, Levicatus Mugenyi5,6, Marike Boezen7,
Thys van der Molen2,8 and Moses R. Kamya1
Abstract
Background: Recent large-scale population data on the prevalence of asthma and its risk factors are lacking in
Uganda. This survey was conducted to address this data gap.
Methods: A general population based survey was conducted among people ≥12 years. A questionnaire was used
to collect participants socio-demographics, respiratory symptoms, medical history, and known asthma risk factors.
Participants who reported wheeze in the past 12 months, a physician diagnosis of asthma or current use of asthma
medications were classified as having asthma. Asthmatics who were ≥ 35 years underwent spirometry to determine
how many had fixed airflow obstruction (i.e. post bronchodilator forced expiratory volume in one second/forced
vital capacity (FEV1/FVC) ratio < lower limit of normal (LLN). Descriptive statistics were used to summarize
participants’ characteristics. Prevalence of asthma was calculated as a proportion of asthmatics over total survey
population. To obtain factors independently associated with asthma, a random-effects model was fitted to the data.
Results: Of the 3416 participants surveyed, 61.2% (2088) were female, median age was 30 years (IQR, 20–45) and
323 were found to have asthma. Sixteen people with asthma ≥35 years had fixed airflow obstruction. The
prevalence of asthma was 11.0% (95% CI:8.9–13.2; males 10.3%, females 11.4%, urban 13.0% and rural 8.9%.
Significantly more people with asthma smoked than non-asthmatics: 14.2% vs. 6.3%, p < 0.001, were exposed to
biomass smoke: 28.0% vs. 20.0%, p < 0.001, had family history of asthma: 26.9% vs. 9.4%, p, < 0.001, had history of
TB: 3.1% vs. 1.30%, p = 0.01, and had hypertension: 17.9% vs. 12.0%, p = 0. 003. In multivariate analysis smoking,
(adjusted odds ratio (AOR), 3.26 (1.96–5.41, p < 0.001) family history of asthma, AOR 2.90 (98–4.22 p- < 0.001), nasal
congestion, AOR 3.56 (2.51–5.06, p < 0.001), biomass smoke exposure, AOR 2.04 (1.29–3.21, p = 0.002) and urban
residence, AOR 2.01(1.23–3.27, p = 0.005) were independently associated with asthma.
Conclusion: Asthma is common in Uganda and is associated with smoking, biomass smoke exposure, urbanization,
and allergic diseases. Health care systems should be strengthened to provide asthma care. Measures to reduce
exposure to the identified associated factors are needed.
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Background
Asthma is estimated to affect 334 million people globally [1].
Recent large-scale population data on the prevalence of
asthma and its risk factors are lacking in Uganda in particu-
lar and Africa in general. The world health survey conducted
between 2002 and 2003 reported an asthma prevalence of
4–8% in the studied African countries [1]. A systematic re-
view by Adeloye et al. found that the weighted mean preva-
lence of asthma was 7.0% in the rural areas (2.5–11.5) and
9.6% (3.9–15.2) in urban areas [2]. The same systematic re-
view also indicates that the number of people suffering from
asthma in Africa has increased from 74.4 million in 1990 to
119.3 million in 2010.
In addition to genetic susceptibility, several factors
have been found to be associated with asthma [3]. These
factors include exposure to allergens such as pollen and
house dust mites, indoor air pollution (biomass smoke)
and outdoor air pollution, tobacco smoking including
second hand smoke (especially in children), urban resi-
dence and viral respiratory infections [3–7].
Diagnosing asthma is challenging as there is no gold
standard test. A combination of characteristic clinical fea-
tures and various tests (spirometry, airway inflammation,
bronchial hyper-responsiveness testing, allergy testing) is
used to arrive at a diagnosis in a clinical setting [8]. In sur-
veys however, extensive clinical evaluation and testing is
often not possible, hence surveys have relied mainly on
symptom questionnaires. The three most commonly used
questionnaires are those used in international study of
asthma and allergy in childhood (ISAAC), the European
community respiratory health survey (ECRHS) and the
world health survey questionnaires [1, 9, 10].
To fill the data gap on asthma prevalence and its risk
factors in Uganda, we aimed to conduct a national gen-
eral population based survey.
Methods
Design and study participants
This study was a cross-sectional general population based
survey in five districts in Uganda: Kampala (urban) and
Iganga, Kiruhura, Maracha and Pader (rural), Fig. 1. The
overall calculated sample size was 2936 participants (518
from each of 4 rural districts and 864 from Kampala)
based on the assumption of an asthma prevalence of 8%, a
precision of 0.03 and a design effect of 1.5 (to account for
the cluster design). Clusters (villages) were selected by
Fig. 1 Survey districts (highlighted in blue), based on UN map of Uganda- including new districts by region
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probability proportionate to size by Uganda Bureau of Sta-
tistics using the Uganda National population and housing
census of 2014. Households within clusters were selected
by simple random sampling from a household list gener-
ated by village leaders. All persons aged ≥12 who were
members of selected household and provided written in-
formed consent (and assent in case of minors) were sur-
veyed. Exclusion criteria were: residency of congregation
settings (schools, prisons, homes) and temporary residents
(less than 2 weeks in household of selected villages). Ac-
cording to the Uganda National population and housing
census of 2014, the average number of persons 12 years
and older in a household was estimated to be 2.5 persons
and the average number of households per cluster was 90
households. Based on these estimates we surveyed a total
of 1408 households in 60 clusters across the country; 20
clusters in Kampala and 20 households from each of the
clusters and in rural districts we surveyed 10 clusters and
25 households from each of the districts.
Survey implementation
In this survey three field teams each comprising of one
supervisor, two interviewers, one spirometry technician, one
district tuberculosis and leprosy supervisor (DTLS), one local
council 1 leader (LC1), one driver and community volunteers
as needed was used. Each team surveyed one cluster per day
(i.e. about 50 participants/day). The implementation of the
survey commenced with the training of the survey teams.
Thereafter, a pilot was undertaken to test survey human re-
sources, study tools and the designed data system. After the
pilot, adjustments to the tools and the data management sys-
tem were made. The teams were retrained. Halfway into the
survey, amid term review was conducted to inform the in-
vestigators of any needed adjustments and strategies to en-
hance the survey quality.
Survey procedures
Sampled participants were interviewed by trained research as-
sistants using a standardized questionnaire developed by
adapting questions from internationally recognized question-
naires, namely the World Health Organization (WHO) health
survey [1, 10], the ISAAC [10] and ECRHS surveys [9]. Partic-
ipants who reported either wheeze in the last 12months, his-
tory of current use of asthma medications at the time of the
survey or history of ever having a physician diagnosis of
asthma were considered to be asthmatics.
Anthropometric measurements were measured; height
(measured without shoes to the nearest 0.1-cm using a stadi-
ometer [SECA; Hamburg, Germany]) and weight (measured
without shoes and in light clothing to the nearest 0.1 kg
using a calibrated beam scale). Blood pressure (BP) was mea-
sured using an Omron automated sphygmomanometer
model HEM-907, which has an adjustable cuff size. Partici-
pants assumed a resting seated posture ≥10min prior to two
sequential BP readings taken 10min apart. We considered
the average of the two BP readings as the individual’s BP.
Participants with systolic BP > 130 and diastolic BP > 90 were
considered to have hypertension for purposes of this
analysis.
Participants who fulfilled the criteria for asthma on ques-
tionnaire and were ≥ 35 years underwent spirometry testing
to assess for presence of fixed airflow obstruction. The 35
year cut off limit was chosen because fixed air flow obstruc-
tion increases with age and based on our previous surveys
we found many persons with fixed airflow obstruction from
age 35 years and older [11]. Participants identified as having
asthma were referred to nearest health facilities for further
evaluation and management. Spirometry was conducted and
interpreted according to American Thoracic Society/Euro-
pean Respiratory Society guidelines using a Pneumotrac®
spirometer with Spirotrac® V software (Vitalograph Ltd.,
Buckingham, United Kingdom) [12]. Spirometry was per-
formed with participant seated and with a nose clip applied.
Testing continued until at least three acceptable and repro-
ducible blows with the largest and second-largest values for
both forced vital capacity (FVC) and forced expiratory vol-
ume in 1 s (FEV 1) within 150mL or no more than 5% differ-
ence; the largest values for FVC and FEV 1 were considered
the best and used for analysis. Spirometers were calibrated
every morning with a 3 L syringe. Pre-bronchodilator spir-
ometry was performed. Participants whose FEV1/FVC ratio
was less than 80% underwent post bronchodilator spirometry
(i.e. repeat spirometry 15min after inhalation of 400 micro-
grams of inhaled salbutamol). On a daily basis, a physician
reviewed all spirograms and those that did not meet the
quality criteria were repeated the following day. Predicted pa-
rameters were based on NHANES III models as in built
within the Spirotrac® V spirometers program used [13]. Par-
ticipants whose post bronchodilator FEV1/FVC ratio was less
than the LLN ie, participants below the fifth percentile of the
predicted FEV 1 /FVC ratio (calculated with GLI2012 Data
Conversion software; version 3.3.1) were classified as having
fixed airflow obstruction [14, 15]. However these participants
were not excluded from asthma participants on this basis.
Ethical approval
Ethics approval was obtained from the Mulago Hospital Re-
search and Ethics committee and the Uganda National
Council for Science and Technology. Participants provided
written informed consent and were free to terminate study
participation at any time during the study. For children be-
tween the ages of 12–18 years we obtained their written
assent and written parental/legal guardian consent.
Statistical analysis
The planned sample size was 2936 participants, sufficient
to provide a precise national, rural vs. urban and male vs.
female estimates assuming a national asthma prevalence
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of 8%. Urban setting was defined as any areas gazette by
the government of Uganda as urban during the 2014 na-
tional housing and population census [16].
Prevalence of asthma was calculated as the proportion of
participants with asthma in the survey population and pre-
sented with 95% confidence intervals (95% CI). Weighting to
account for clustering due to the cluster design of the survey
was performed. A weight, which is the reciprocal of the over-
all selection probability (p) was generated as 1/p where p =
p1*p2*p3 with p1, p2 and p3 being the probabilities of selecting
a district, a cluster within a district, and a household within a
cluster, respectively. Later, “svy:” command in Stata was used
to apply the weights when estimating the prevalence and
other statistics. Because weighted and unweighted prevalence
estimates differed, we present the weighted prevalence esti-
mates in this manuscript. Descriptive statistics was used to
summarize participants’ characteristics.
To obtain factors independently associated with asthma, a
random-effects model was fitted to the data [17]. All factors
that were individually associated with asthma with p-value<
0.20 and demographic factors were subjected to multivari-
able analysis using a random-effects model. To arrive at a
better fit, backward model building was conducted using
likelihood ratio test (LRT), the multicollinearity was checked
using the variance inflation factor (VIF). The results from a
better fit and free from multicollinearity (VIF < 10) are pre-
sented as adjusted estimates. Data was analyzed using
STATA (StataCorp. 2011. Stata Statistical Software: Release
12. College Station, TX: StataCorp LP).
Results
Characteristics of study participants
From September 15th to October 10th, 2016, 4310 par-
ticipants were invited and 3416 participated (participa-
tion rate of 79.3%). Of 3416 participants, 61.2% (2088)
were female, 22.78% (778) were of urban residence and
the median age was 30 years (IQR 20–45). Further de-
tails of participants’ characteristics are shown in Table 1.
Prevalence of asthma
Overall 323 participants were found to have asthma.
Three hundred and eighteen of 323 asthmatic partici-
pants (9.3%), 58/323 (1.7%), and 25/323 (0.7%) reported
to have had wheezing the past 12 months, had ever had
physician’s diagnosis of asthma, and were currently using
asthma medications at the time of the survey, respect-
ively. A Venn diagram showing overlaps between these
three measures of asthma is presented in Fig. 2. The
weighted prevalence of asthma was 11.02% (95% CI:
8.87–13.17), males 10.27% (95% CI: 7.88–12.65), females
11.40% (95% CI: 8.71–14.09), urban 12.99% (95% CI:
9.03–16.95), rural 8.86% (95% CI: 7.74–9.98), Table 2.
Among both males and females, the asthma prevalence
increased with increasing age, Fig. 3.
Comparison of characteristics of asthmatic and non-
asthmatic survey participants
More asthmatics than non-asthmatics reported tobacco
smoke exposure 14.2% vs. 6.3%, p < 0.001, biomass smoke
exposure 28.0% vs. 19.7%, p < 0.001, family history of
asthma 26.9% vs. 9.4%, p, <0.001, history of tuberculosis
(TB) 3.1% vs. 1.3%, p = 0.010, and hypertension 17.9% vs.
12.0%, p = 0. 003, Additional file 1: Table S1.
The proportions of participants with allergy and respira-
tory symptoms by asthma status are presented in Additional
file 1: Table S2A &2B. Nasal congestion in the past 12
months was reported by 40.3% of asthmatics vs. 13.2%
non-asthmatics, p < 0.001). Itchy watery eyes were reported
Table 1 Characteristics of study participants (social,
demographic, risk factors, respiratory and allergy symptoms, and

















Nasal congestion in the past 12 months 538 15.75
Itchy-watery eyes in the past 12 months 767 22.45
Skin rash in the past 12 months 408 11.96
Rash affected other areas 261 62.74
Respiratory symptoms
Cough 711 20.83
Shortness of breath 309 9.05
Chest pain 873 25.56
Sputum production 257 7.52
Risk factors
History of/passive smoking 242 7.09
Exposure to bio-mass† 698 20.44
Family history of asthmaΦ 377 11.05
History of TB treatment 50 1.45
HIV positive 103 3.02
Hypertensive 426 12.58
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by 40.6% of asthmatics vs. 20.6% non-asthmatics, p < 0.001)
while skin rash was reported by 20.7% of asthmatics vs.
11.0% non- asthmatics, p < 0.001. The proportions of the dif-
ferent respiratory symptoms by asthma vs. non-asthma sta-
tus respectively were: cough (51.7% vs. 17.6%, p= < 0.001),
shortness of breath (40.3% vs.5.8%, p < 0.001), chest pain
(56.7% vs. 22.3%, p < 0.001) and sputum production (28.5%
vs. 5.3%, p < 0.00).
Factors associated with asthma
The factors independently associated with asthma in this
survey as obtained from an adjusted random-effects model
were: smoking, adjusted odds ratio (AOR) 3.26 (95%
CI:1.96–5.41, p < 0.001), family history of asthma, AOR 2.90
(95% CI: 1.98–4.22 p- <0.001), nasal congestion in the past
12months, AOR 3.56 (95% CI: 2.51–5.06, p < 0.001), bio-
mass smoke exposure, AOR 2.04 (95% CI: 1.29–3.21, p=
0.02) and urban residence, AOR 2.01(95% CI: 1.23–3.27, p=
0.05), Table 3. All respiratory symptoms were associated with
asthma, AORs (95% CIs) of: cough 2.41 (1.66–3.50, p <
0.001), shortness of breath 6.84 (4.57–10.23, p < 0.001), chest
pain 3.00 (2.15–4.19, p < 0.001) and sputum production 1.81
(1.16–2.88, p= 0.009), Table 3. The factors associated with
asthma in a model that considers only factors associated with
asthma with a p-value less 0.05 at a bivariate stage are shown
in Additional file 1: Table S3.
Fixed airflow obstruction
Of the 323 participants who were classified as having asthma
on the questionnaire, 138 (42.72%) were 35 years and older
and therefore eligible for spirometry. Of these, 120 (86.96%)
underwent spirometry and 18(13.04%) did not. We obtained
interpretable spirometry in 106 of the 120 (88.33%). After
post bronchodilator testing, 16 of the 106 participants who
underwent spirometry were confirmed to have fixed airflow
Fig. 2 A Venn-diagram showing asthma prevalence by three diagnostic criteria and overlap between them
Table 2 Prevalence of asthma (Overall, by residence, gender,
and age group
Unweighted number Weighted prevalence
n/N % 95% CI
Overall 323/3416 11.02 8.87–13.17
Residence
Rural 227/2637 8.86 7.74–9.98
Urban 96/779 12.99 9.03–16.95
Gender
Male 114/1327 10.27 7.88–12.65
Female 209/2089 11.40 8.71–14.09
Age group
<15 19/372 7.99 1.89–14.09
15–24 54/883 8.68 5.44–11.93
25–34 65/681 10.56 6.75–14.37
35–44 66/577 14.42 9.99–18.85
45–54 53/475 11.81 8.09–15.53
55–64 31/225 14.37 7.17–21.57
65+ 35/201 13.66 8.06–19.25
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obstruction (15.09%), 13(12.26%) had significantly reversible
airflow obstruction (i.e. FEV1 reversibility of > 12% or >
200mls) and 9 (8.49%) had a restriction.
Discussion
This survey found an asthma prevalence of 11.02% in
Uganda, higher in urban areas than rural areas (12.99% vs.
8.86%) and among those aged 35–44 years (14.42%) com-
pared to those either younger or older than those in this
age group. No significant differences were found by gen-
der (female 11.40% and male 10.27%). Significant associa-
tions were found between asthma and smoking, family
history of asthma, nasal congestion, biomass smoke ex-
posure, urban residence, and all respiratory symptoms.
Asthmatic and non-asthmatic participants had statistically
significant differences in the rates of history of TB (3.10%
vs. 1.30% and hypertension (17.87% vs. 12.03%).
The prevalence of asthma and its higher rate in urban
areas found in this survey are comparable to the prevalence
reported in previous asthma surveys in Africa [1, 2, 18, 19].
There are no prior asthma surveys in Uganda among adoles-
cents and adults apart from one report of history of asthma
in pregnant women (6.0%. was reported) [20] Although the
sex differences in asthma prevalence were small, the differ-
ence was bigger among rural participants (female 9.35% vs.
8.16% for males) than urban participants (females 13.22% vs.
males 12.91%). The bigger difference in rural areas could
be due to biomass smoke exposure, which is greater in fe-
males. Biomass smoke exposure has been found to be as-
sociated with asthma in this study and several previous
studies [19, 21]. The smaller difference in urban areas
could be attributed to higher ambient air pollution. We
have previously shown that air quality in Kampala, where
the urban sample was drawn, exceeds safety limits by 5
times [22].
Analysis of the relation between age and asthma shows
that asthma peaked in the 35–44 age groups with another
peak in those > 55 years. The peak in the 35–44 age group is
previously reported [23]. The second peak of asthma that we
observed in this study could be due to chronic obstructive
pulmonary disease (COPD) that increases in prevalence with
increasing age [24] and given the fact that we defined asthma
by symptoms such as wheeze which can overlap with those
of COPD. It is therefore possible that some of the patients
that we counted as asthma could have had COPD. The
prevalence of COPD has been found to be as high as 16% in
some places in Uganda [11]. To address the issue of older
asthmatics having COPD we analyzed the data taking all
those who had fixed airflow obstruction as COPD and found
that only 5% of all asthmatic could be reclassified as COPD.
Our results therefore support other studies’ findings
that asthma is an important respiratory disease in
older people [25]. It must be noted however that
fixed airflow obstruction can occur in asthmatics even
in the absence of COPD due to airway remodeling
with long standing asthma especially if care is sub-
optimal. There are several risk factors for this occur-
rence namely severe asthma, long-standing and poorly
treated or untreated disease, late onset asthma, smok-
ing, frequent exacerbations, ongoing exposures to
asthma triggers, persistent eosinophilic airway inflam-
mation and asthma-COPD overlap [19, 26–29]. In
Fig. 3 Prevalence of asthma by age group and gender
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this survey 98.5% of the asthmatics were neither diag-
nosed nor on asthma treatment that could have led
to fixed airflow obstruction.
This survey confirmed the association of several known
risk factors with asthma namely smoking, biomass expos-
ure, allergy, respiratory symptoms, and urban residence.
We were also able to show a significant association between
biomass smoke exposure and asthma. The rates of TB and
hypertension were statistically significantly higher among
asthmatics in comparison to non-asthmatics: TB (3.10% vs.
1.30%, p = 0.010) and hypertension (17.87% vs. 12.03%,
p0.003). TB has been reported to be associated with asthma
in previous studies including a large South Africa popula-
tion based study [19, 30]. Although the data is limited, the
association between hypertension and asthma has also been
previously reported [31–33].
This survey had limitations of geographical coverage
(only 5 districts included), not including questions to as-
sess occupational asthma and being conducted in the
wet season without comparison with the dry season. Al-
though we had large numbers of males and females the
overall proportion of males was lower in the sample. We
adjusted for this difference in all analyses but this could
have introduced a bias in the sex differences in the
prevalence. Although, cross-sectional data cannot be
used to draw conclusions on causality, the identified risk
factors are well in line with previous prospective studies
in other populations.
Table 3 Factors associated with asthma
Factors With asthma Without Asthma Crude estimates Adjusted estimates
n (%) n (%) Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value
History of /passive smoking
Yes 46 (14.24) 196 (6.34) 2.80 (1.89–4.14) <0.001 3.26 (1.96–5.41) <0.001
No 277 (85.76) 2896 (93.66) 1 1
Family history of asthmaΦ
Yes 87 (26.93) 290 (9.39) 3.57 (2.68–4.76) <0.001 2.90 (1.98–4.22) <0.001
No 236 (73.07) 2800 (90.61) 1 1
Nasal congestion in the past 12 months
Yes 130 (40.25) 408 (13.20) 5.06 (3.79–6.75) <0.001 3.56 (2.51–5.06) <0.001
No 193 (59.75) 2684 (86.80) 1 1
Cough
Yes 167 (51.70) 544 (17.60) 6.48 (4.76–8.82) <0.001 2.41 (1.66–3.50) <0.001
No 156 (48.30) 2547 (82.40) 1 1
Shortness of breath
Yes 130 (40.25) 179 (5.79) 14.24 (9.90–20.50) 6.84 (4.57–10.23) <0.001
No 193 (59.75) 2911 (94.21) 1 1
Chest pain
Yes 183 (56.66) 690 (22.32) 5.35 (4.04–7.08) <0.001 3.00 (2.15–4.19) <0.001
No 140 (43.34) 2402 (77.68) 1 1
Sputum production
Yes 92 (28.48) 165 (5.33) 9.01 (6.22–13.07) <0.001 1.83 (1.16–2.89) 0.009
No 231 (71.52) 2928 (94.67) 1 1
Exposure to bio-mass†
Yes 90 (27.95) 608 (19.66) 1.60 (1.20–2.14) 0.001 2.04 (1.29–3.21) 0.002
No 232 (72.05) 2485 (80.34) 1 1
Residence
Urban 96 (29.72) 683 (22.08) 1.48 (1.11–1.97) 0.007 2.01 (1.23–3.27) 0.005
Rural 227 (70.28) 2410 (77.92) 1
Sex:
Female 209 (64.71) 1880 (60.78) 1.17 (0.91–1.50) 0.227 1.25 (0.89–1.74) 0.195
Male 114 (35.29) 1213 (39.22) 1 1
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Conclusion
Asthma is common in Uganda and is associated with
smoking, biomass smoke exposure, urbanization, and al-
lergic diseases. Health care systems should be strength-
ened to provide asthma care. Measures to reduce
exposure to the identified associated factors are needed.
Additional file
Additional file 1: This file contains 4 tables that present additional data
obtained in the survey that we consider important to publish. Additional
file 1: Table S1 provides data of the comparison of the social,
demographic and clinical characteristics of participants with asthma and
those without asthma in the survey, Additional file 1: Table S2A presents
allergy characteristics of the participants by asthma status while
Additional file 1: Table S2B presents the respiratory symptoms of the
participants by asthma status. Additional file 1: Table S3 presents
findings of a multivariate model of the factors associated with asthma
considering only factors associated with asthma at the bivariate stage
with p-value less than 0.05. (DOCX 38 kb)
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